Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
about
[Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].[Calculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Comparison of methods].Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.[Differences in chronic back pain and joint disorders among health insurance funds : Results of a cross-sectional study based on the data of the Socioeconomic Panel from 2013].Microcosting quantity data collection methods.Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.Determinants of direct costs in Dutch rheumatoid arthritis patients.Direct costs related to rheumatoid arthritis: the patient perspective.Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyBiologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?Systematic review of studies of productivity loss due to rheumatoid arthritis.Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveWork in inflammatory and degenerative joint diseases.The impact of rheumatoid arthritis and biologics on employers and payers.Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees.Medical costs for Korean patients with rheumatoid arthritis based on the national claims database.Treatment costs of attention deficit hyperactivity disorder in Germany.Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.Paid expenditures and productivity costs associated with permanent disability pensions in patients with spinal disorders: Nationwide Finnish Register-based Study, 1990-2010.Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.The costs of colonoscopy in a Canadian hospital using a microcosting approachSocietal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study.
P2860
Q30572825-9B661659-2917-4377-954D-957CBC85E44BQ30596477-B284AE31-8BE8-4CCB-83C5-291A2C7EB5FCQ31019080-2C32F291-7E18-413A-94D3-2382889E3109Q31122174-BB96431C-8832-4741-BB51-3E243C7FF591Q33470193-15C281B1-1D1F-4C30-A407-4FA238FAC4A2Q33871768-830551A4-77BA-4F11-991B-7A7B7AC7D8DEQ35554259-4F7FB28F-6901-4036-97B2-B963A4B47FDCQ35554873-487C36E0-C9D3-4E51-82E4-A8B6F2D8B43BQ35555089-457BBAE0-FCD1-419B-8FEB-DB9C9DCE6C1EQ35637894-0D2674BE-AA45-4B09-99CE-5FADE4C49DB7Q35851000-3B7D9ADE-FD6C-475D-BFD1-D8824483B9C6Q35953211-136FDCE7-C64D-4708-AE2E-76ACD895E698Q36312507-29AEDD65-2127-453E-B79B-A983A3F837ABQ36439036-328E10E3-FE3D-4F41-BC6A-D492128C9620Q36923056-B7AE514F-5EA1-46D8-92B3-779B01902412Q37251489-49020A96-2EEF-4320-9DE8-A884FA59E382Q37255093-5D6EC2D9-A0B6-4C92-802A-771F6DBE90A9Q37928497-0F2A2964-0500-4963-9AC0-4E7C40E800B2Q38062338-506DD86C-B975-4BD2-A14A-940019D7A299Q40455661-804E5E1A-3B16-443E-AE22-0464132D1D66Q40905089-9DE20219-38AF-4E63-8A49-F728AD79B07AQ41510090-1650D037-C213-4485-91BC-CBBCA519E548Q41912381-5A391951-F0FA-4591-A1EC-87917EF00AB1Q42005633-48D4167D-471D-4808-A403-0CEE815C72D3Q44051129-5740B876-106F-4CEF-8C8A-29AA9BD23C5C
P2860
Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@ast
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@en
type
label
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@ast
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@en
prefLabel
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@ast
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@en
P2093
P2860
P356
P1476
Costs of rheumatoid arthritis ...... althcare payer's data sources.
@en
P2093
Handelmann S
Hülsemann JL
Merkesdal S
Mittendorf T
von der Schulenburg JM
P2860
P304
P356
10.1136/ARD.62.6.544
P407
P577
2003-06-01T00:00:00Z